List of insiders holdings for Chemomab Therapeutics Ltd.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| # | Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| 1 | THIEL PETER 10% Owner | 2026-02-17 16:48:53 | 22,631,200 0 | 22,631,200 | Form 13G |
| 2 | Access Industries Holdings LLC Clal Biotechnology Industries Ltd. ACCESS INDUSTRIES LLC ACCESS INDUSTRIES MANAGEMENT LLC Blavatnik Len 10% Owner | 2021-04-15 17:28:03 | 5,057,766 0 | 5,057,766 | Form 13D |
| 3 | Gabriel Capital Management Ltd. 10% Owner | 2022-02-10 16:02:58 | 3,087,040 0 | 3,087,040 | Form 13G |
| 4 | Haluska Frank Chief Executive Officer | 2020-01-02 16:33:58 | 2,148,236 0 | 2,148,236 | Form 3 |
| 5 | OrbiMed Israel GP Ltd. OrbiMed Israel BioFund GP Limited Partnership 10% Owner | 2025-06-23 17:06:15 | 969,807 0 | 969,807 | Form 13D |
| 6 | Pfost Dale R Chief Executive Officer | 2022-03-15 16:10:10 | 461,853 0 | 461,853 | Form 4 |
| 7 | VERU DENNISON T Director | 2020-01-02 16:34:21 | 81,900 369,640 | 451,540 | Form 3 |
| 8 | Burgin Jonathan See Remarks | 2020-01-02 16:34:45 | 340,037 0 | 340,037 | Form 3 |
| 9 | Kerstein David Chief Medical Officer | 2020-01-02 16:31:04 | 340,000 0 | 340,000 | Form 3 |
| 10 | Knickerbocker Ron See Remarks | 2020-01-02 16:32:13 | 235,000 0 | 235,000 | Form 3 |
| 11 | Marvin Donald Executive VP, CFO & COO | 2022-06-21 06:01:38 | 198,875 0 | 198,875 | Form 4 |
| 12 | SQUINTO STEPHEN P Director | 2021-04-21 17:16:57 | 168,624 0 | 168,624 | Form 4 |
| 13 | Frankel Matthew Bejosa Chief Medical Officer | 2022-11-15 16:03:38 | 125,000 0 | 125,000 | Form 3 |
| 14 | Gilon Ohev-Zion Michal VP, Research and Development | 2020-01-02 16:33:35 | 100,254 0 | 100,254 | Form 3 |
| 15 | Daly Sean T VP, Clinical Operations | 2020-01-02 16:32:44 | 80,000 0 | 80,000 | Form 3 |
| 16 | Fatal Sigal Chief Financial Officer | 2026-04-10 16:07:07 | 79,415 0 | 79,415 | Form 3 |
| 17 | Aharon Arnon Chief Medical Officer | 2021-03-25 10:11:21 | 75,232 0 | 75,232 | Form 3 |
| 18 | HOWARD LAWRENCE Director | 2020-01-02 16:30:40 | 55,000 15,385 | 70,385 | Form 3 |
| 19 | Mor George Adi Chief Executive Officer | 2026-06-01 07:33:22 | 69,212 0 | 69,212 | Form 4 |
| 20 | Lawler John Chief Development Officer | 2026-04-10 16:04:35 | 61,512 0 | 61,512 | Form 3 |
| 21 | Alon Ruth Director | 2020-01-02 16:35:08 | 55,353 0 | 55,353 | Form 3 |
| 22 | Makov Efrat Director | 2020-01-02 16:31:25 | 55,353 0 | 55,353 | Form 3 |
| 23 | Polovets Stanislav Director | 2021-03-12 16:28:05 | 55,000 0 | 55,000 | Form 4 |
| 24 | HARDY REGINALD L Director | 2020-01-02 16:35:30 | 55,000 0 | 55,000 | Form 3 |
| 25 | Kohlberg Isaac T. Director | 2020-01-02 16:31:51 | 55,000 0 | 55,000 | Form 3 |
| 26 | Cohen Neil Harris Director | 2026-04-10 16:10:36 | 53,379 0 | 53,379 | Form 3 |
| 27 | Roshan Salar Head of Business Development | 2020-01-02 16:33:06 | 30,000 0 | 30,000 | Form 3 |
| 28 | Darvish Nissim Director | 2026-04-10 16:12:30 | 25,184 0 | 25,184 | Form 3 |
| 29 | Maryles Joel Michael Director | 2022-05-25 16:03:50 | 20,137 0 | 20,137 | Form 4 |
| 30 | Nicaise Claude Director | 2026-03-31 16:02:06 | 17,903 0 | 17,903 | Form 3 |
| 31 | Moses Alan Charles Director | 2026-04-10 16:08:28 | 17,903 0 | 17,903 | Form 3 |
| 32 | Quigley Jill M. Director | 2026-03-31 16:03:22 | 11,616 0 | 11,616 | Form 3 |
| 33 | Melincoff Gwen A Director | 2026-06-03 16:19:05 | 8,621 0 | 8,621 | Form 3 |
| 34 | Fine Andrew Chief Financial Officer | 2021-03-11 18:34:09 | 0 0 | 0 | Form 3 |
| 35 | DiPalma Stephen J. Chief Financial Officer | 2020-05-07 16:16:21 | 0 0 | 0 | Form 3 |
| 36 | Gonen Ofer Director | 2020-01-02 17:08:41 | 0 0 | 0 | Form 3 |